Physician profile
Rachel Jeanette Kohls
NPI 1275907024
$3,630.89
in general payments reported to CMS, 2019-2025
35 companies · $1,649 in 2025
The $1,649 reported for 2025 was more than what 94% of Clinical Nurse Specialist providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $263 · 2022: $486 · 2023: $680 · 2024: $553 · 2025: $1,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,304 · Travel and Lodging: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,304.06 |
| Travel and Lodging | $577.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,385.00 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $328.98 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $234.66 | 2023-2025 | Freestyle Libre 3, Eterna |
| Lilly USA, LLC | $228.24 | 2021-2024 | Mounjaro, Jardiance |
| Dexcom, INC. | $144.12 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $107.49 | 2021-2024 | |
| Amgen INC. | $101.58 | 2023-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $85.61 | 2022-2025 | |
| Beta Bionics, INC. | $81.71 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Corcept Therapeutics | $81.22 | 2023-2025 | Korlym |
| Insulet Corporation | $76.39 | 2022-2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $65.98 | 2022-2023 | |
| Ascensia Diabetes Care US INC. | $63.59 | 2021-2025 | |
| Cequr Corporation | $59.21 | 2023-2024 | Cequr Simplicity |
| Astrazeneca Pharmaceuticals Lp | $57.84 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $51.90 | 2021-2025 | Gvoke Hypopen |
| Ibsa Pharma INC. | $51.74 | 2021-2024 | Tirosint, Licart |
| Antares Pharma, INC. | $40.42 | 2024 | Xyosted, Tlando |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.21 | 2022-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $35.99 | 2022-2025 | |
| Soleno Therapeutics, INC. | $31.89 | 2025 | Vykat Xr |
| Acella Pharmaceuticals, LLC | $30.10 | 2021-2025 | NP Thyroid 60 |
| Mannkind Corporation | $26.98 | 2023 | Afrezza |
| Amneal Pharmaceuticals LLC | $24.45 | 2025 | Unithroid |
| Chiesi USA, INC. | $23.35 | 2024 | Mycapssa |
| Radius Health, INC. | $22.25 | 2025 | Tymlos |
| Sequel Med Tech, LLC | $21.64 | 2025 | Twiist |
| Horizon Therapeutics Plc | $17.96 | 2022 | |
| Vistapharm, INC. | $17.09 | 2021 | |
| Grt US Holding, INC. | $16.96 | 2022 | |
| Intuity Medical INC | $16.91 | 2022 | |
| Alvogen INC | $16.69 | 2023 | Teriparatide |
| Halozyme INC | $15.32 | 2023 | |
| Tolmar, INC. | $15.24 | 2025 | Jatenzo |
| Recordati_rare_diseases_inc. | $15.18 | 2024 | Isturisa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Kohls listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.